Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Operating Leases (2019 - 2025)

Historic Operating Leases for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to $98480.5.

  • Innate Pharma's Operating Leases rose 511.4% to $98480.5 in Q2 2025 from the same period last year, while for Jun 2025 it was $98480.5, marking a year-over-year increase of 511.4%. This contributed to the annual value of $91998.8 for FY2024, which is 5.74% up from last year.
  • Per Innate Pharma's latest filing, its Operating Leases stood at $98480.5 for Q2 2025, which was up 511.4% from $90830.6 recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Operating Leases peaked at $98480.5 during Q2 2025, and registered a low of $16859.8 during Q2 2021.
  • For the 5-year period, Innate Pharma's Operating Leases averaged around $70844.4, with its median value being $76224.7 (2023).
  • As far as peak fluctuations go, Innate Pharma's Operating Leases plummeted by 4533.3% in 2021, and later skyrocketed by 34935.89% in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's Operating Leases stood at $60630.5 in 2021, then plummeted by 44.47% to $33668.2 in 2022, then surged by 171.64% to $91454.9 in 2023, then fell by 0.68% to $90830.6 in 2024, then rose by 8.42% to $98480.5 in 2025.
  • Its Operating Leases stands at $98480.5 for Q2 2025, versus $90830.6 for Q4 2024 and $93689.2 for Q2 2024.